Literature DB >> 4629075

Enteric immunization with live adenovirus type 21 vaccine. II. Systemic and local immune responses following immunization.

R M Scott, B A Dudding, S V Romano, P K Russell.   

Abstract

Studies of the immunologic responses following administration of a live, enteric-coated adenovirus (ADV) type 21 vaccine showed that nine of ten vaccinees and none of five controls developed neutralizing antibody. Antibody activity of serum and secretory immunoglobulins was assayed by using a (14)C-labeled ADV-21 antigen in a radioimmunodiffusion system. Increases in immunoglobulin M, A and G (IgM, IgA, IgG) activity were detected in sera from vaccinees but not in those from controls. IgA copro antibody activity was also shown in vaccinees but not in controls. Nasal secretions showed no detectable IgA antibody responses by this method. These studies show marked differences in serum and local IgA antibody activity in induced enteric ADV infection compared to previously reported responses after natural infection. The protective role of secretory IgA in adenovirus infections is obscure. However, absence of nasal IgA responses may indicate that protection against disease with enteric ADV vaccines depends primarily upon humoral antibody.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4629075      PMCID: PMC422365          DOI: 10.1128/iai.5.3.300-304.1972

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  13 in total

1.  IDENTIFICATION OF THE ANTIVIRAL SUBSTANCES IN NASAL SECRETIONS.

Authors:  M S ARTENSTEIN; J A BELLANTI; E L BUESCHER
Journal:  Proc Soc Exp Biol Med       Date:  1964-11

2.  Viremia and viruria in adenovirus infections. Detection in patients with rubella or rubelliform illness.

Authors:  R R GUTEKUNST; A D HEGGIE
Journal:  N Engl J Med       Date:  1961-02-23       Impact factor: 91.245

3.  Acute respiratory illness in volunteers following intramuscular administration of live adenovirus.

Authors:  M R HILLEMAN; R E HODGES; M S WARFIELD; S A ANDERSON
Journal:  J Clin Invest       Date:  1957-07       Impact factor: 14.808

4.  Experimental respiratory infection with type 4 adenovirus vaccine in volunteers: clinical and immunological responses.

Authors:  T J Smith; E L Buescher; F H Top; W A Altemeier; J M McCown
Journal:  J Infect Dis       Date:  1970-10       Impact factor: 5.226

5.  Control of acute mycoplasmal and viral respiratory tract disease.

Authors:  R M Chanock
Journal:  Science       Date:  1970-07-17       Impact factor: 47.728

6.  Immunization by selective infection with type 4 adenovirus grown in human diploid tissue culture. II. specific protective effect against epidemic disease.

Authors:  W P Edmondson; R H Purcell; B F Gundelfinger; J W Love; W Ludwig; R M Chanock
Journal:  JAMA       Date:  1966-02-07       Impact factor: 56.272

7.  Immunoglobulin responses in serum and nasal secretions after natural adenovirus infections.

Authors:  J A Bellanti; M S Artenstein; B L Brandt; B S Klutinis; E L Buescher
Journal:  J Immunol       Date:  1969-11       Impact factor: 5.422

8.  Distribution of poliovirus antibody in serum, nasopharynx and alimentary tract following segmental immunization of lower alimentary tract with poliovaccine.

Authors:  P L Ogra; D T Karzon
Journal:  J Immunol       Date:  1969-06       Impact factor: 5.422

9.  Method for extracting viral hemagglutination-inhibiting antibodies from the nonspecific inhibitors of serum.

Authors:  W A Altemeier; F K Mundon; F H Top; P K Russell
Journal:  Appl Microbiol       Date:  1970-05

10.  Enteric immunization with live adenovirus type 21 vaccine. I. Tests for safety, infectivity, immunogenicity, and potency in volunteers.

Authors:  B A Dudding; P J Bartelloni; R M Scott; F H Top; P K Russell; E L Buescher
Journal:  Infect Immun       Date:  1972-03       Impact factor: 3.441

View more
  13 in total

1.  Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres.

Authors:  K Allaoui-Attarki; S Pecquet; E Fattal; S Trollé; E Chachaty; P Couvreur; A Andremont
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

2.  Pathology of exfoliated oropharyngeal epithelial cells infected with wild-type adenovirus.

Authors:  D P McCormick; Q Galapon; C Berling
Journal:  Appl Microbiol       Date:  1972-09

3.  Increased jejunal IgA synthesis in vitro during acute infectious nonbacterial gastroenteritis.

Authors:  S G Agus; Z M Falchuk; C S Sessoms; R G Wyatt; R Dolin
Journal:  Am J Dig Dis       Date:  1974-02

4.  Variability of human systemic humoral immune responses to adenovirus gene transfer vectors administered to different organs.

Authors:  B G Harvey; N R Hackett; T El-Sawy; T K Rosengart; E A Hirschowitz; M D Lieberman; M L Lesser; R G Crystal
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

5.  Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines.

Authors:  B R Murphy; D L Nelson; P F Wright; E L Tierney; M A Phelan; R M Chanock
Journal:  Infect Immun       Date:  1982-06       Impact factor: 3.441

6.  Genotype prevalence and risk factors for severe clinical adenovirus infection, United States 2004-2006.

Authors:  Gregory C Gray; Troy McCarthy; Mark G Lebeck; David P Schnurr; Kevin L Russell; Adriana E Kajon; Marie L Landry; Diane S Leland; Gregory A Storch; Christine C Ginocchio; Christine C Robinson; Gail J Demmler; Michael A Saubolle; Sue C Kehl; Rangaraj Selvarangan; Melissa B Miller; James D Chappell; Danielle M Zerr; Deanna L Kiska; Diane C Halstead; Ana W Capuano; Sharon F Setterquist; Margaret L Chorazy; Jeffrey D Dawson; Dean D Erdman
Journal:  Clin Infect Dis       Date:  2007-09-27       Impact factor: 9.079

7.  Active synthesis of hemagglutinin-specific immunoglobulin A by lung cells of mice that were immunized intragastrically with inactivated influenza virus vaccine.

Authors:  K S Chen; D B Burlington; G V Quinnan
Journal:  J Virol       Date:  1987-07       Impact factor: 5.103

8.  Enteric immunization with live adenovirus type 21 vaccine. I. Tests for safety, infectivity, immunogenicity, and potency in volunteers.

Authors:  B A Dudding; P J Bartelloni; R M Scott; F H Top; P K Russell; E L Buescher
Journal:  Infect Immun       Date:  1972-03       Impact factor: 3.441

9.  Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum.

Authors:  D K Wagner; M L Clements; C B Reimer; M Snyder; D L Nelson; B R Murphy
Journal:  J Clin Microbiol       Date:  1987-03       Impact factor: 5.948

10.  Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain.

Authors:  Byoung-Shik Shim; Konrad Stadler; Huan Huu Nguyen; Cheol-Heui Yun; Dong Wook Kim; Jun Chang; Cecil Czerkinsky; Man Ki Song
Journal:  Virol J       Date:  2012-09-21       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.